TY - JOUR
T1 - Clinical evaluation of the QMS® Tacrolimus Immunoassay
AU - Leung, Edward Ki Yun
AU - Yi, Xin
AU - Gloria, Carmelita
AU - Yeo, Kiang Teck J.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2014/4/20
Y1 - 2014/4/20
N2 - Background: Tacrolimus, a widely used immunosuppressant, inhibits T-lymphocyte signal transduction and cytokine upregulation. We evaluated and compared the performance of a newly developed tacrolimus immunoassay method to LC-MS/MS. Method: Analytical performance was assessed using quality control materials and whole blood patient samples. Interferences studies were performed using pooled whole-blood samples spiked with each interferent, respectively. Comparison studies were conducted using 145 de-identified whole blood samples collected after routine tacrolimus analysis by LC-MS/MS. Results: CVs were between 3.9 and 8.1% and the method was linear (r2=0.99) up to 30.0ng/ml. Calibration was stable ≤12days and LOQ was 0.7ng/ml (14.4% CV). Bilirubin (≤48mg/dl), hemoglobin (≤345mg/dl), and triglycerides (<2800mg/dl) showed no significant interference. Comparison (Passing-Bablok regression) for all samples showed a proportional bias of 17%. Comparisons of liver and kidney transplant patients showed slope biases of 22% and 31%, respectively, whereas other remaining transplant patients (stem cell, heart, lung, and islet) showed a slope bias of 0.98. Conclusions: Overall, the QMS Tacrolimus Immunoassay showed good analytical performance. Comparison studies showed a proportional bias of 17%, which can be attributed to the significant number of liver and kidney transplant patients present in this study (121/145).
AB - Background: Tacrolimus, a widely used immunosuppressant, inhibits T-lymphocyte signal transduction and cytokine upregulation. We evaluated and compared the performance of a newly developed tacrolimus immunoassay method to LC-MS/MS. Method: Analytical performance was assessed using quality control materials and whole blood patient samples. Interferences studies were performed using pooled whole-blood samples spiked with each interferent, respectively. Comparison studies were conducted using 145 de-identified whole blood samples collected after routine tacrolimus analysis by LC-MS/MS. Results: CVs were between 3.9 and 8.1% and the method was linear (r2=0.99) up to 30.0ng/ml. Calibration was stable ≤12days and LOQ was 0.7ng/ml (14.4% CV). Bilirubin (≤48mg/dl), hemoglobin (≤345mg/dl), and triglycerides (<2800mg/dl) showed no significant interference. Comparison (Passing-Bablok regression) for all samples showed a proportional bias of 17%. Comparisons of liver and kidney transplant patients showed slope biases of 22% and 31%, respectively, whereas other remaining transplant patients (stem cell, heart, lung, and islet) showed a slope bias of 0.98. Conclusions: Overall, the QMS Tacrolimus Immunoassay showed good analytical performance. Comparison studies showed a proportional bias of 17%, which can be attributed to the significant number of liver and kidney transplant patients present in this study (121/145).
KW - Immunoassay
KW - Interference
KW - LC-MS/MS
KW - Method comparison
KW - Tacrolimus
UR - http://www.scopus.com/inward/record.url?scp=84896049469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896049469&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2014.01.027
DO - 10.1016/j.cca.2014.01.027
M3 - Article
C2 - 24518359
AN - SCOPUS:84896049469
VL - 431
SP - 270
EP - 275
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
ER -